New Indication: Osimertinib in First-Line NSCLC

  • Study

    Multi-center, phase 2 nonrandomized clinical trial (UNICORN)
    Previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion mutations.
    Osimertinib (n=40)


  • Efficacy

    ORR: 55.0% [40.9-68.5]
    mPFS: 9.4 mos [3.7-15.2]
    mOS: NR [19.3-NR]

  • Safety

    Grade3: Interstitial lung disease (12.5%)


    • JAMA Oncol NOV 22, 2023

    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations, The UNICORN Phase 2 Nonrandomized Clinical Trial

    http://doi.org/10.1001/jamaoncol.2023.5013

    Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag